These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14592486)

  • 1. Novel DNA/polymer conjugate for intelligent antisense reagent with improved nuclease resistance.
    Murata M; Kaku W; Anada T; Sato Y; Kano T; Maeda M; Katayama Y
    Bioorg Med Chem Lett; 2003 Nov; 13(22):3967-70. PubMed ID: 14592486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific inhibition of hepatitis C viral gene expression by non-polar (phenylalkyl)phosphonates.
    Amberg S; Tamke A; Caselmann WH; Engels JW
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1631-4. PubMed ID: 14565483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of antisense oligodeoxynucleotides to inhibit expression of glutamate transporter subtypes.
    Bristol LA; Rothstein JD
    Methods Enzymol; 1998; 296():514-29. PubMed ID: 9779471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression.
    Uhlmann E; Peyman A; Ryte A; Schmidt A; Buddecke E
    Methods Enzymol; 2000; 313():268-84. PubMed ID: 10595361
    [No Abstract]   [Full Text] [Related]  

  • 5. Antisense oligodeoxynucleotides downregulated c-sis mRNA expression to inhibit proliferation of vascular smooth muscle cells.
    Tang QD; Lin SG; Yu XY
    Zhongguo Yao Li Xue Bao; 1999 Jan; 20(1):36-42. PubMed ID: 10437122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antisense properties of oligodeoxyribonucleotides containing C5-substituted arabinofuranosyluracil.
    Ozaki H; Nakajima K; Kuwahara M; Sawai H
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1115-8. PubMed ID: 14980647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of antisense drug design against conservative local motif in simulant secondary structures of HER-2 mRNA and QSAR analysis.
    Yang SP; Song ST; Tang ZM; Song HF
    Acta Pharmacol Sin; 2003 Sep; 24(9):897-902. PubMed ID: 12956938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) for effective antisense formation.
    Morita K; Yamate K; Kurakata S; Watanabe K; Imanishi T; Koizumi M
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1619-21. PubMed ID: 14565480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells.
    Li S; Deshmukh HM; Huang L
    Pharm Res; 1998 Oct; 15(10):1540-5. PubMed ID: 9794495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A method to select chemically modified aptamers directly.
    Boiziau C; Toulmé JJ
    Antisense Nucleic Acid Drug Dev; 2001 Dec; 11(6):379-85. PubMed ID: 11838639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective degradation of targeted mRNAs using partially modified oligonucleotides.
    Dagle JM; Weeks DL
    Methods Enzymol; 2000; 313():420-36. PubMed ID: 10595370
    [No Abstract]   [Full Text] [Related]  

  • 14. Towards the selection of phosphorothioate aptamers optimizing in vitro selection steps with phosphorothioate nucleotides.
    Andreola ML; Calmels C; Michel J; Toulmé JJ; Litvak S
    Eur J Biochem; 2000 Aug; 267(16):5032-40. PubMed ID: 10931185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense candidates against protein kinase C-alpha designed based on phylogenesis and simulant structure of mRNA.
    Song HF; Tang ZM; Yuan SJ; Zhu BZ; Liu XW
    Acta Pharmacol Sin; 2003 Mar; 24(3):269-76. PubMed ID: 12617778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages.
    Oishi M; Nagatsugi F; Sasaki S; Nagasaki Y; Kataoka K
    Chembiochem; 2005 Apr; 6(4):718-25. PubMed ID: 15756696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo delivery of antisense oligodeoxynucleotides using lipofection: application of antisense technique to growth suppression of experimental glioma.
    Matsuno A; Nagashima T; Katayama H; Tamura A
    Methods Enzymol; 2000; 313():359-72. PubMed ID: 10595366
    [No Abstract]   [Full Text] [Related]  

  • 18. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H; Chi KN; Gleave ME
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene switching: analyzing a broad range of mutations using steric block antisense oligonucleotides.
    Morcos PA
    Methods Enzymol; 2000; 313():174-89. PubMed ID: 10595356
    [No Abstract]   [Full Text] [Related]  

  • 20. Design of antisense and triplex-forming oligonucleotides.
    François JC; Lacoste J; Lacroix L; Mergny JL
    Methods Enzymol; 2000; 313():74-95. PubMed ID: 10595350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.